Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H26FN3O2 |
Molecular Weight | 383.4591 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(OCCCN2CCC3(CC2)N(CNC3=O)C4=CC=CC=C4)C=C1
InChI
InChIKey=FJUKDAZEABGEIH-UHFFFAOYSA-N
InChI=1S/C22H26FN3O2/c23-18-7-9-20(10-8-18)28-16-4-13-25-14-11-22(12-15-25)21(27)24-17-26(22)19-5-2-1-3-6-19/h1-3,5-10H,4,11-17H2,(H,24,27)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11124389Curator's Comment: the description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17965538 | https://www.ncbi.nlm.nih.gov/pubmed/11277763 | https://www.ncbi.nlm.nih.gov/pubmed/19875674 | https://www.ncbi.nlm.nih.gov/pubmed/11078195
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11124389
Curator's Comment: the description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17965538 | https://www.ncbi.nlm.nih.gov/pubmed/11277763 | https://www.ncbi.nlm.nih.gov/pubmed/19875674 | https://www.ncbi.nlm.nih.gov/pubmed/11078195
Spiramide (AMI-193) is a spiperone derivative, a selective 5-HT2A, (Ki = 2 nM) 5-HT1A (Ki = 50 nM), and D2 receptor (Ki = 3 nM) antagonist, with negligible affinity for the 5-HT2C receptor (Ki = 4300 nM). The ability of Spiramide to serve as a functional 5-HT2A antagonist in behavioral studies was demonstrated through studies in which Spiramide blocked the discriminative - stimulus effects of the 5HT2A agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL273 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8355253 |
50.0 nM [Ki] | ||
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11078195 |
2.0 nM [Ki] | ||
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11124389 |
4300.0 nM [Ki] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8355253 |
3.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
New diterpene alkaloids from the roots of Spiraea japonica. | 2001 Mar |
|
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. | 2004 Aug |
|
Possible involvement of endogenous 5-HT in aggravation of cerulein-induced acute pancreatitis in mice. | 2007 Nov |
|
5-hydroxytryptamine receptor stimulation of mitochondrial biogenesis. | 2010 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11124389
0.003 and 0.01 mg/ kg
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19875674
Female New Zealand White rabbits renal proximal tubular cells (RPTC) were isolated using the iron oxide perfusion method and grown in 35-mm tissue culture dishes. The culture medium was a 1:1 mixture of Dulbecco’s modified Eagle’s medium/Ham’s F-12 (without glucose, phenol red, or sodium pyruvate) supplemented with 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 mkM pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 ng/ml), human transferrin (5 mkg/ml), bovine insulin (10 nM), and L-ascorbic acid-2-phosphate (50 mkM) were added daily to fresh culture medium. RPTC monolayers were treated with either the pan-5-HT receptor antagonist AM-193 (Spiramide) (10 mkM) or vehicle control (dimethyl sulfoxide) for 30 min and then exposed to DOI (10 mkM) for 12 h.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1665
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
510-74-7
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
68186
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
64207
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
C66559
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
C003338
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
Spiramide
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
100000083803
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
DTXSID6042579
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL79834
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
471LF4O004
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY | |||
|
SUB10619MIG
Created by
admin on Sat Dec 16 17:04:38 GMT 2023 , Edited by admin on Sat Dec 16 17:04:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY